Concepedia

William J. Kell

WJ

6

Publications

898

Citations

6

H-Index

2003

Active since

Affiliations

Leicester Royal Infirmary(Current)

Heartlands Hospital

University Hospital of Wales

University of Birmingham

Cardiff University

William J. Kell is an author at Leicester Royal Infirmary specializing in hematology, pharmacotherapy, and cancer research.

Top concepts

Publications per year

2003–2012

6

Publications

6

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

Steven Knapper, Alan K. Burnett, Tim Littlewood et al. · Blood · 2006 · 393 citations · Full text

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

William J. Kell · Blood · 2003 · 180 citations · Full text

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

Alan K. Burnett, Robert K. Hills, Ann E. Hunter et al. · Leukemia · 2012 · 158 citations · Full text

, , +9

The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial.

Alan K. Burnett, William J. Kell, Anthony H. Goldstone et al. · Blood · 2006 · 78 citations

Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cells

Richard G. Goodwin, William J. Kell, P. Laidler et al. · Blood · 2005 · 60 citations · Full text

Rows per page

1–5 of 6